ZambiaTuberculosis profile
Population  2016 17 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.8 (2.8–7.3) 29 (17–44)
Mortality (HIV+TB only) 12 (7.9–18) 74 (47–107)
Incidence  (includes HIV+TB) 62 (40–89) 376 (244–535)
Incidence (HIV+TB only) 36 (23–52) 218 (140–312)
Incidence (MDR/RR-TB)** 2.1 (1.4–2.9) 13 (8.4–17)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 3.6 (2.2–4.9) 20 (12–28) 24 (15–33)
Males 4 (2.5–5.6) 34 (21–48) 38 (23–53)
Total 7.6 (4.6–11) 55 (33–76) 62 (40–89)
TB case notifications, 2016  
Total cases notified 40 153
Total new and relapse 38 326
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 93%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 50%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 62% (43–95)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.29 (0.16–0.43)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 21 655 58%
          - on antiretroviral therapy 17 914 83%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 400
(910–1 900)
Estimated % of TB cases with MDR/RR-TB 1.1% (0.13–2.1) 18% (12–25)  
% notified tested for rifampicin resistance <1% 7% 526
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 180, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 136, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 85% 36 741
Previously treated cases, excluding relapse, registered in 2015 84% 4 847
HIV-positive TB cases registered in 2015 87% 20 967
MDR/RR-TB cases started on second-line treatment in 2014 51% 68
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 14
Funding source: 9% domestic, 52% international, 40% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-20 Data: www.who.int/tb/data